Stock LRMR LARIMAR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
9.59 USD +0.95% Intraday chart for Larimar Therapeutics, Inc. +19.88% +110.77%
May. 31 Health Care Stocks Climb On Drug News -- Health Care Roundup DJ
May. 31 Larimar Therapeutics Shares Rise 15% Nomlabofusp Selected for FDA Program DJ

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
United States Food and Drug Administration Selects Larimar Therapeutics, Inc. to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia
Sector Update: Health Care Stocks Steady Premarket Tuesday
Sector Update: Health Care
Top Premarket Gainers
Larimar Therapeutics Gets Partial Hold Lifted on Study of Nervous System Disorder Treatment; Shares Soar Premarket
Larimar Therapeutics Gets Partial Hold Lifted on Study of Nervous System Disorder Treatment
Larimar Therapeutics Announces FDA Has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich?S Ataxia
Larimar Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Zafgen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Larimar Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Sector Update: Health Care Stocks Gain Premarket Tuesday
Larimar Therapeutics Doses 1st Patient in Study of Movement Disorder Treatment
Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich?S Ataxia
Top Midday Gainers
Larimar Therapeutics Starts Public Offering of Common Shares, Pre-Funded Warrants
Top Midday Gainers
Larimar Therapeutics Says Potential Friedreich's Ataxia Drug Well-Tolerated in Phase 2 Study
Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia
Larimar Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LRMR Stock
  4. News Larimar Therapeutics, Inc.
  5. Other languages